Invion Limited Stock

Equities

IVX

AU000000IVX4

Biotechnology & Medical Research

Market Closed - Australian S.E. 08:04:18 2024-04-16 pm EDT 5-day change 1st Jan Change
0.005 AUD 0.00% Intraday chart for Invion Limited 0.00% 0.00%
Sales 2022 3.29M 2.12M Sales 2023 4.1M 2.64M Capitalization 25.69M 16.52M
Net income 2022 -2M -1.29M Net income 2023 -1M -643K EV / Sales 2022 15 x
Net cash position 2022 8.47M 5.45M Net cash position 2023 4.08M 2.63M EV / Sales 2023 5.26 x
P/E ratio 2022
-22.6 x
P/E ratio 2023
-13.4 x
Employees 4
Yield 2022 *
-
Yield 2023
-
Free-Float 50.95%
More Fundamentals * Assessed data
Dynamic Chart
1 week
0.01
Extreme 0.005
0.01
1 month
0.01
Extreme 0.005
0.01
Current year
0.00
Extreme 0.004
0.01
1 year
0.00
Extreme 0.004
0.01
3 years
0.00
Extreme 0.004
0.03
5 years
0.00
Extreme 0.004
0.03
10 years
0.00
Extreme 0.002
0.09
More quotes
Managers TitleAgeSince
Chief Executive Officer - 17-11-30
Director of Finance/CFO 51 20-07-12
Investor Relations Contact - -
Members of the board TitleAgeSince
Director/Board Member - 20-10-21
Chief Executive Officer - 17-11-30
Director/Board Member 74 19-02-11
More insiders
Date Price Change Volume
24-04-17 0.005 0.00% 12,910
24-04-16 0.005 0.00% 134,044
24-04-15 0.005 -9.09% 638,542
24-04-11 0.0055 +10.00% 265,678

Delayed Quote Australian S.E., April 16, 2024 at 08:04 pm EDT

More quotes
Invion Limited is an Australia-based life sciences company. The Company is engaged in the research and development of Photosoft technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. The Company is engaged in the clinical development of a PhotoDynamic Therapy (PDT) for cancer. Its photosensitizer (the agent used in PDT) is called IVX-PDT and is based on Photosoft Technology. Its PDT is an alternative to surgery, and in contrast to radiotherapy and chemotherapy, which are immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumor by leukocytes. It produces topical and intravenous products suitable for use in skin cancer and in solid tumors, such as those present in ovarian, prostate and lung cancer. It is developing a topical formulation of its photosensitizing agent, IVX-PDT, to treat superficial Basal Cell Carcinoma (sBCC), Actinic Keratosis (AK) and Squamous Cell Cancer (SCC).
More about the company